|Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)|
|By: GlobenewsWire - 22 Jul 2021||Back to overview list
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds increased on 21 July 2021 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Point B: Financial instruments according to SMA 9:6a:
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Copyright 2021 GlobenewsWire
|Back to overview list|